These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 16061098)

  • 1. Bimatoprost.
    Medeiros FA; Susanna R
    Ophthalmology; 2005 Aug; 112(8):1478; author reply 1479. PubMed ID: 16061098
    [No Abstract]   [Full Text] [Related]  

  • 2. Mechanism of ocular hypotensive action of bimatoprost (Lumigan) in patients with ocular hypertension or glaucoma.
    Christiansen GA; Nau CB; McLaren JW; Johnson DH
    Ophthalmology; 2004 Sep; 111(9):1658-62. PubMed ID: 15350319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bimatoprost: establishing its role in glaucoma management.
    Katz LJ
    Surv Ophthalmol; 2004 Mar; 49 Suppl 1():S1-4. PubMed ID: 15016555
    [No Abstract]   [Full Text] [Related]  

  • 4. Latanoprost versus bimatoprost.
    Eisenberg D
    Ophthalmology; 2003 Sep; 110(9):1861-2; author reply 1862. PubMed ID: 13129903
    [No Abstract]   [Full Text] [Related]  

  • 5. Cost considerations in the medical management of glaucoma in the US: estimated yearly costs and cost effectiveness of bimatoprost compared with other medications.
    Soto J
    Pharmacoeconomics; 2006; 24(5):519-20; author reply 520-2. PubMed ID: 16706575
    [No Abstract]   [Full Text] [Related]  

  • 6. Mechanism of action of bimatoprost (Lumigan).
    Brubaker RF
    Surv Ophthalmol; 2001 May; 45 Suppl 4():S347-51. PubMed ID: 11434937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of monotherapy treatment of glaucoma and ocular hypertension with the lipid class of medications.
    Kymes S
    Am J Ophthalmol; 2006 Aug; 142(2):354; author reply 354-5. PubMed ID: 16876536
    [No Abstract]   [Full Text] [Related]  

  • 8. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator, multicenter study.
    Bernstein P
    Am J Ophthalmol; 2004 Feb; 137(2):387-8; author reply 388-9. PubMed ID: 14962451
    [No Abstract]   [Full Text] [Related]  

  • 9. Intraocular pressure-lowering efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension.
    Noecker R
    Br J Ophthalmol; 2006 Nov; 90(11):1336-7. PubMed ID: 17057169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Additivity of bimatoprost or travoprost to latanoprost in glaucomatous monkey eyes.
    Gagliuso DJ; Wang RF; Mittag TW; Podos SM
    Arch Ophthalmol; 2004 Sep; 122(9):1342-7. PubMed ID: 15364714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical pharmacology of bimatoprost.
    Cantor LB
    Expert Opin Drug Metab Toxicol; 2005 Jun; 1(1):151-7. PubMed ID: 16922657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The safety and efficacy of bimatoprost/timolol fixed combination: a 1-year double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertension.
    Lewis RA; Gross RL; Sall KN; Schiffman RM; Liu CC; Batoosingh AL;
    J Glaucoma; 2010 Aug; 19(6):424-6. PubMed ID: 19855289
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost.
    Gandolfi SA; Cimino L
    Ophthalmology; 2003 Mar; 110(3):609-14. PubMed ID: 12623831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two new ophthalmic solutions enter glaucoma market.
    Am J Health Syst Pharm; 2001 Jun; 58(12):1080, 1086. PubMed ID: 11449848
    [No Abstract]   [Full Text] [Related]  

  • 15. Flare-up rates with bimatoprost therapy in uveitic glaucoma.
    Fortuna E; Cervantes-Castañeda RA; Bhat P; Doctor P; Foster CS
    Am J Ophthalmol; 2008 Dec; 146(6):876-82. PubMed ID: 19027422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the effects of bimatoprost and a fixed combination of latanoprost and timolol on circadian intraocular pressure.
    Rossetti L; Karabatsas CH; Topouzis F; Vetrugno M; Centofanti M; Boehm A; Viswanathan A; Vorwerk C; Goldblum D
    Ophthalmology; 2007 Dec; 114(12):2244-51. PubMed ID: 17459480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostaglandin analogs and blood-aqueous barrier integrity: a flare cell meter study.
    Cellini M; Caramazza R; Bonsanto D; Bernabini B; Campos EC
    Ophthalmologica; 2004; 218(5):312-7. PubMed ID: 15334011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of monotherapy treatment of glaucoma and ocular hypertension with the lipid class of medications.
    Noecker RJ; Walt JG
    Am J Ophthalmol; 2006 Jan; 141(1 Suppl):S15-21. PubMed ID: 16389056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ocular hypotensive efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension.
    Cantor LB; WuDunn D; Cortes A; Hoop J; Knotts S
    Surv Ophthalmol; 2004 Mar; 49 Suppl 1():S12-8. PubMed ID: 15016557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, investigator-masked comparison of diurnal responder rates with bimatoprost and latanoprost in the lowering of intraocular pressure.
    Choplin N; Bernstein P; Batoosingh AL; Whitcup SM;
    Surv Ophthalmol; 2004 Mar; 49 Suppl 1():S19-25. PubMed ID: 15016558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.